Applied Genetic Technologies Corporation (AGTC): Price and Financial Metrics

Applied Genetic Technologies Corporation (AGTC): $1.57

-0.09 (-5.42%)

POWR Rating

Component Grades













Add AGTC to Watchlist
Sign Up

Industry: Biotech


of 453

in industry


  • AGTC scores best on the Growth dimension, with a Growth rank ahead of 69.62% of US stocks.
  • AGTC's strongest trending metric is Stability; it's been moving down over the last 168 days.
  • AGTC's current lowest rank is in the Stability metric (where it is better than 9.02% of US stocks).

AGTC Stock Summary

  • With a price/sales ratio of 142.31, Applied Genetic Technologies Corp has a higher such ratio than 98.09% of stocks in our set.
  • As for revenue growth, note that AGTC's revenue has grown -79.62% over the past 12 months; that beats the revenue growth of only 1.76% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AGTC comes in at -112.28% -- higher than that of only 3.5% of stocks in our set.
  • Stocks that are quantitatively similar to AGTC, based on their financial statements, market capitalization, and price volatility, are SYBX, BBI, LIFE, CBIO, and ALT.
  • AGTC's SEC filings can be seen here. And to visit Applied Genetic Technologies Corp's official web site, go to

AGTC Valuation Summary

  • In comparison to the median Healthcare stock, AGTC's price/sales ratio is NA% NA, now standing at NA.
  • Over the past 90 months, AGTC's price/sales ratio has gone NA NA.
  • AGTC's price/sales ratio has moved NA NA over the prior 90 months.

Below are key valuation metrics over time for AGTC.

Stock Date P/S P/B P/E EV/EBIT
AGTC 2021-08-31 NA 1.6 -2.5 -1.3
AGTC 2021-08-30 NA 1.6 -2.5 -1.3
AGTC 2021-08-27 NA 1.6 -2.6 -1.4
AGTC 2021-08-26 NA 1.6 -2.5 -1.3
AGTC 2021-08-25 NA 1.6 -2.5 -1.3
AGTC 2021-08-24 NA 1.6 -2.5 -1.3

AGTC Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -247.17%.
  • The 4 year net income to common stockholders growth rate now stands at -247.17%.
  • Its 3 year net cashflow from operations growth rate is now at -131.48%.
Over the past 49 months, AGTC's revenue has gone down $37,481,000.

The table below shows AGTC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.5 -54.192 -59.568
2021-06-30 0.5 -51.173 -57.829
2021-03-31 0 -51.504 -60.196
2020-12-31 0 -48.892 -56.534
2020-09-30 2.453 -43.822 -49.695
2020-06-30 2.453 -41.62 -45.892

AGTC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AGTC has a Quality Grade of D, ranking ahead of 17.04% of graded US stocks.
  • AGTC's asset turnover comes in at 0.005 -- ranking 411th of 682 Pharmaceutical Products stocks.
  • HSTO, PLXP, and ABBV are the stocks whose asset turnover ratios are most correlated with AGTC.

The table below shows AGTC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 1 -1.382
2021-03-31 0.000 NA -1.146
2020-12-31 0.000 NA -1.079
2020-09-30 0.026 1 -0.945
2020-06-30 0.026 1 -0.842
2020-03-31 0.031 1 -0.796

AGTC Price Target

For more insight on analysts targets of AGTC, see our AGTC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.78 Average Broker Recommendation 1.33 (Strong Buy)

AGTC Stock Price Chart Interactive Chart >

Price chart for AGTC

AGTC Price/Volume Stats

Current price $1.57 52-week high $9.67
Prev. close $1.66 52-week low $1.40
Day low $1.55 Volume 372,173
Day high $1.67 Avg. volume 374,048
50-day MA $1.99 Dividend yield N/A
200-day MA $3.17 Market Cap 67.30M

Applied Genetic Technologies Corporation (AGTC) Company Bio

Applied Genetic Technologies is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed for patients with severe diseases in ophthalmology. The company was founded in 1999 and is based in Alachua, Florida.

AGTC Latest News Stream

Event/Time News Detail
Loading, please wait...

AGTC Latest Social Stream

Loading social stream, please wait...

View Full AGTC Social Stream

Latest AGTC News From Around the Web

Below are the latest news stories about Applied Genetic Technologies Corp that investors may wish to consider to help them evaluate AGTC as an investment opportunity.

Applied Genetic exceeds enrollment target in AGTC-501 trial for vision loss

Applied Genetic Technologies (AGTC +3.4%) has exceeded the enrollment target in its SKYLINE trial of AGTC-501, a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa (XLRP), an inherited condition that causes progressive vision loss in boys and young men. A total of 14 patients have...

Seeking Alpha | January 11, 2022

Applied Genetic Technologies (AGTC) Receives a Buy from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Applied Genetic Technologies (AGTC – Research Report), with a price target of $24.00. The company's shares closed last Tuesday at $1.81. According to, Pantginis ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -11.1% and a 26.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Actinium Pharmaceuticals, and Iovance Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Applied Genetic Technologies with a $14.00 average price target.

Brian Anderson on TipRanks | January 11, 2022

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022Company providing further updated guidance on other milestones GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of r

Yahoo | January 11, 2022

AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that Sue Washer, President & Chief Executive Officer, and Susan Schneider M.D., Chief Medical Office

Yahoo | January 4, 2022

An Assessment Of Applied Genetic Technologies Corporation

No summary available.

Seeking Alpha | December 14, 2021

Read More 'AGTC' Stories Here

AGTC Price Returns

1-mo -16.04%
3-mo -39.38%
6-mo -56.39%
1-year -64.72%
3-year -46.78%
5-year -80.74%
YTD -17.37%
2021 -53.55%
2020 -9.51%
2019 81.53%
2018 -30.83%
2017 -61.50%

Continue Researching AGTC

Want to see what other sources are saying about Applied Genetic Technologies Corp's financials and stock price? Try the links below:

Applied Genetic Technologies Corp (AGTC) Stock Price | Nasdaq
Applied Genetic Technologies Corp (AGTC) Stock Quote, History and News - Yahoo Finance
Applied Genetic Technologies Corp (AGTC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.811 seconds.